Hepatitis C (Hep C) is a viral liver infection that affects an estimated 58 million people worldwide. The good news: modern direct-acting antiviral (DAA) treatments can cure over 95% of Hep C cases within 8-12 weeks. This guide compares the leading Hep C treatments available through Indian generic manufacturers — Sofosbuvir, Velpatasvir, and Daclatasvir — and helps you understand which regimen may be right for you.
What Is Hepatitis C and How Is It Treated?
Hepatitis C is caused by the hepatitis C virus (HCV), which attacks the liver. Chronic infection can lead to cirrhosis, liver failure, or liver cancer if left untreated. Modern treatments use direct-acting antivirals (DAAs) that target specific steps in the HCV replication process, stopping the virus from multiplying and allowing the body to clear the infection.
The standard of care in 2026 involves combination therapy — two or more DAAs taken together — to prevent drug resistance and maximize cure rates. Treatment typically lasts 8 to 12 weeks with minimal side effects compared to older interferon-based regimens.
Key HCV Medications Compared
Sofosbuvir (Sovaldi)
Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor. It forms the backbone of most modern Hep C regimens. It is effective against all HCV genotypes (1-6) and is typically combined with Velpatasvir, Daclatasvir, or Ledipasvir.
- Dosage: 400 mg once daily
- Duration: 8-12 weeks (in combination)
- Cure rate: >95% when combined with appropriate partner drug
- Sovaldi 400 mg (Mylan) — 28 tablets: approximately $624-$763 at 984degree.com
Velpatasvir
Velpatasvir is an NS5A inhibitor that works synergistically with Sofosbuvir. The combination Sofosbuvir + Velpatasvir (brand name: Epclusa) is a pan-genotypic regimen, meaning it works against all HCV genotypes, making it the most versatile treatment option.
- Dosage: 100 mg once daily (combined with Sofosbuvir 400 mg in one tablet)
- Duration: 12 weeks (or 8 weeks for non-cirrhotic patients with genotype 1-6)
- Cure rate: 96-98%
- Velpanat 400/100 mg (Zydus) — 28 tablets: approximately $245-$299
- MyHep All (Beacon) — 28 tablets: approximately $250-$306
Daclatasvir
Daclatasvir is another NS5A inhibitor commonly combined with Sofosbuvir for patients who cannot tolerate or access Velpatasvir-based regimens. The Sofosbuvir + Daclatasvir combination is highly effective against genotype 1, 3, and 4.
- Dosage: 60 mg once daily
- Duration: 12 weeks
- Cure rate: 95-98% (genotype 1, 3, 4)
- Natdac 60 mg (Natco) — 28 tablets: approximately $79-$97
- Dacihep 60 mg (Zydus) — 28 tablets: approximately $80-$97
Which Regimen Is Best for You?
| Regimen | Genotypes Covered | Duration | Cure Rate | Indian Generic Option |
|---|---|---|---|---|
| Sofosbuvir + Velpatasvir | 1-6 (pan-genotypic) | 8-12 weeks | 96-98% | Velpanat, MyHep All, Velasof |
| Sofosbuvir + Daclatasvir | 1, 3, 4 | 12 weeks | 95-98% | Velasof/Resof Total |
| Sofosbuvir + Ledipasvir | 1, 4, 5, 6 | 8-12 weeks | 95-99% | Hepcinat LP, Myhep LVIR |
Sofosbuvir + Velpatasvir is generally recommended as first-line therapy because it covers all genotypes. Sofosbuvir + Daclatasvir is an excellent alternative, particularly for genotype 3, and is often more affordable.
Cost Comparison: US Brand vs Indian Generic
The price difference between brand-name DAAs in the US and Indian generics is extraordinary:
| Treatment | US Brand Price (12-week course) | Indian Generic Price (12-week course) | Savings |
|---|---|---|---|
| Sofosbuvir + Velpatasvir | $24,000-$74,000 | $735-$900 | 97-99% |
| Sofosbuvir + Daclatasvir | $30,000-$63,000 | $750-$950 | 97-99% |
Indian generic manufacturers like Natco, Zydus Cadila, Mylan, Hetero, and Beacon produce WHO-prequalified versions of these life-saving medications at a fraction of Western prices.
Where to Buy Affordable Hep C Treatment from India
Licensed Indian online pharmacies offer genuine DAAs with international shipping. 984degree.com stocks several WHO-approved Hep C medications:
- Velpanat 400/100 mg (Zydus) — Sofosbuvir + Velpatasvir: ~$245-$299 per bottle
- MyHep All (Beacon) — Sofosbuvir + Velpatasvir: ~$250-$306 per bottle
- Velasof/Resof Total (Natco) — Sofosbuvir + Daclatasvir: ~$232-$283 per bottle
- Natdac 60 mg (Natco) — Daclatasvir: ~$79-$97 per 28 tablets
- Dacihep 60 mg (Zydus) — Daclatasvir: ~$80-$97 per 28 tablets
- Sovaldi 400 mg (Mylan) — Sofosbuvir: ~$624-$763 per 28 tablets
A full 12-week course typically requires 3 bottles of the combination product, totaling approximately $234-$324 for Velpanat (Natco) — a life-saving investment compared to $24,000+ in the US.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Hepatitis C treatment requires a prescription from a qualified healthcare provider. Always undergo appropriate diagnostic testing (HCV RNA, genotype, liver fibrosis assessment) before starting treatment. Prices are approximate and may change. Verify current pricing at the pharmacy before purchasing.
Hepatitis C virus (HCV) infection affects an estimated 58 million people worldwide, with approximately 1.5 million new infections occurring each year. The advent of direct-acting antiviral (DAA) therapy has transformed HCV from a chronic, potentially fatal disease into one that can be cured in over 95% of cases with 8-12 weeks of oral medication. The most widely used DAA regimens combine sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, with velpatasvir, an NS5A inhibitor. This combination, known as Sofosbuvir/Velpatasvir (brand name Epclusa), is pangenotypic, meaning it is effective against all six major HCV genotypes, simplifying treatment by eliminating the need for genotype testing in most cases.
Treatment duration depends on several factors including HCV genotype, presence of cirrhosis, and prior treatment history. For treatment-naive patients without cirrhosis, an 8-week course of sofosbuvir/velpatasvir is typically sufficient. Patients with compensated cirrhosis typically require 12 weeks of therapy. For patients who have failed prior DAA treatment, the addition of ribavirin or extending treatment to 24 weeks may be necessary. The presence of resistance-associated substitutions (RASs), particularly in NS5A, can affect treatment outcomes and may require genotype-specific regimen selection. Access to affordable generic DAAs from Indian manufacturers has been a game-changer in global HCV elimination efforts, with a full 12-week course of sofosbuvir/velpatasvir available for $200-400, compared to over $75,000 for the brand-name Epclusa in the United States.
Liver fibrosis staging is essential before initiating HCV treatment, as it determines both treatment duration and the need for ongoing hepatocellular carcinoma (HCC) surveillance after cure. Non-invasive methods such as transient elastography (FibroScan) and APRI/FIB-4 scores are widely used to assess fibrosis stage. Patients with advanced fibrosis (F3) or cirrhosis (F4) require ongoing HCC surveillance with ultrasound every 6 months even after achieving sustained virologic response (SVR), as the risk of HCC, while reduced, remains elevated. During DAA treatment, patients should be monitored for side effects including mild fatigue, headache, and nausea, which are typically self-limited and resolve after completing therapy. Generic daclatasvir, used in combination with sofosbuvir for genotype 3, costs $100-200 for a 12-week course from Indian suppliers.
